Crotamine - Celtic Biotech Iowa
Alternative Names: CB-4Latest Information Update: 21 Jan 2026
At a glance
- Originator Celtic Biotech Iowa
- Class Antineoplastics
- Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Malignant melanoma
Most Recent Events
- 16 Dec 2025 Preclinical trials in Malignant melanoma in USA (Parenteral) (Celtic Biotech Iowa pipeline, September 2025)